Chidamide monotherapy for the treatment of hepatosplenic T-cell lymphoma: A case report / 中国输血杂志

【Objective】 To generate an efficacious therapeutic plan for patients suffered from Hepatosplenic T-cell lymphoma (HSTCL). 【Methods】 A patient diagnosed as HSTCL in January 2016 was observed, and chidamide monotherapy instead of traditional chemotherapy was applied due to the poor performance and infection complications of the patient. 【Results】 The patient has achieved amazing improvements after chidamide monotherapy. As we followed and evaluated recently, the patient has received partial remission and can keep durable remission for 4 years. 【Conclusion】 The study suggests that chidamide is a novel therapeuticchoice in patients with HSTCL.